Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
Abstract Background Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19. Methods In this prospective longitudinal study, 95 individuals with severe COVID-19 were sel...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-10-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-024-10073-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182329451937792 |
|---|---|
| author | Nastaran Injinari Samira Asadollahi Fateme Sefid Maedeh Arshadi Saeedeh Sadat Hosseini Hamed Ghoshouni Fatemeh Soltani Nasim Namiranian Mohammad Hasan Sheikhha Fatemeh Aghaeimeybodi |
| author_facet | Nastaran Injinari Samira Asadollahi Fateme Sefid Maedeh Arshadi Saeedeh Sadat Hosseini Hamed Ghoshouni Fatemeh Soltani Nasim Namiranian Mohammad Hasan Sheikhha Fatemeh Aghaeimeybodi |
| author_sort | Nastaran Injinari |
| collection | DOAJ |
| description | Abstract Background Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19. Methods In this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020–2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All participants were genotyped using RFLP-PCR. Different genotypes of FCGR2A rs1801274 and IL-6R rs2228145 were compared in terms of the recovery process. Results 43.2% of patients were male and 56.8% were female with an average age of 58.20(± 16.214) years. The GA genotype for FCGR2A rs1801274 increased the risk of death (OR = 2.83, P = 0.038) and ventilation (OR = 2.71, P = 0.047) in TCZ-treated individuals. However, there was no risk of death and ventilation with IL-6R rs2228145 (P > 0.05). Additionally, docking analysis showed that not only IL6R but also FCGR2A can be a ligand for TCZ. Conclusion This study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes. |
| format | Article |
| id | doaj-art-ebe08962aa874f63a31394ff93c3ea45 |
| institution | OA Journals |
| issn | 1471-2334 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-ebe08962aa874f63a31394ff93c3ea452025-08-20T02:17:39ZengBMCBMC Infectious Diseases1471-23342024-10-0124111110.1186/s12879-024-10073-0Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19Nastaran Injinari0Samira Asadollahi1Fateme Sefid2Maedeh Arshadi3Saeedeh Sadat Hosseini4Hamed Ghoshouni5Fatemeh Soltani6Nasim Namiranian7Mohammad Hasan Sheikhha8Fatemeh Aghaeimeybodi9Diabetes Research Center, Shahid Sadoughi University of Medical SciencesResearch Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical SciencesDepartment of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical SciencesDepartment of Epidemiology and Biostatistics, School of Public Health, Shahid Sadoughi University of Medical SciencesResearch Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical SciencesDiabetes Research Center, Shahid Sadoughi University of Medical SciencesDiabetes Research Center, Shahid Sadoughi University of Medical SciencesDiabetes Research Center, Shahid Sadoughi University of Medical SciencesAbortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical ScienceDepartment of Internal Medicine, Shahid Sadoughi University of Medical SciencesAbstract Background Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19. Methods In this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020–2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All participants were genotyped using RFLP-PCR. Different genotypes of FCGR2A rs1801274 and IL-6R rs2228145 were compared in terms of the recovery process. Results 43.2% of patients were male and 56.8% were female with an average age of 58.20(± 16.214) years. The GA genotype for FCGR2A rs1801274 increased the risk of death (OR = 2.83, P = 0.038) and ventilation (OR = 2.71, P = 0.047) in TCZ-treated individuals. However, there was no risk of death and ventilation with IL-6R rs2228145 (P > 0.05). Additionally, docking analysis showed that not only IL6R but also FCGR2A can be a ligand for TCZ. Conclusion This study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes.https://doi.org/10.1186/s12879-024-10073-0TocilizumabCOVID-19PolymorphismFCGR2AIL-6 receptor |
| spellingShingle | Nastaran Injinari Samira Asadollahi Fateme Sefid Maedeh Arshadi Saeedeh Sadat Hosseini Hamed Ghoshouni Fatemeh Soltani Nasim Namiranian Mohammad Hasan Sheikhha Fatemeh Aghaeimeybodi Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19 BMC Infectious Diseases Tocilizumab COVID-19 Polymorphism FCGR2A IL-6 receptor |
| title | Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19 |
| title_full | Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19 |
| title_fullStr | Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19 |
| title_full_unstemmed | Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19 |
| title_short | Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19 |
| title_sort | impact of fcgr2a rs1801274 and il 6r rs2228145 polymorphisms on tocilizumab response in the iranian population with severe covid 19 |
| topic | Tocilizumab COVID-19 Polymorphism FCGR2A IL-6 receptor |
| url | https://doi.org/10.1186/s12879-024-10073-0 |
| work_keys_str_mv | AT nastaraninjinari impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT samiraasadollahi impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT fatemesefid impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT maedeharshadi impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT saeedehsadathosseini impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT hamedghoshouni impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT fatemehsoltani impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT nasimnamiranian impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT mohammadhasansheikhha impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 AT fatemehaghaeimeybodi impactoffcgr2ars1801274andil6rrs2228145polymorphismsontocilizumabresponseintheiranianpopulationwithseverecovid19 |